Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments

Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct

UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma